Ohio State University Comprehensive Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.cancer.osu.edu

Clinical Trials

Ph 2 Intensification Regimen for Previously Untreated, Resectable, Advanced Squamous Cell Cancer

Phase 2

Terminated

Conditions: Head and Neck Cancer

Interventions: Drug: Cisplatin
Drug: Paclitaxel
Radiation: Intensity-Modulated Radiation Therapy (IMRT) External Beam Radiation
Procedure: Triple endoscopy and biopsy

First Posted Date: 2007-12-03

Last Posted Date: 2021-11-26

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 11

Registration Number: NCT00566540

Locations: 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States

Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma

Phase 1

Completed

Conditions: Lymphoma
Small Intestine Cancer

Interventions: Drug: vorinostat
Other: Correlative studies

First Posted Date: 2007-11-21

Last Posted Date: 2015-07-16

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 23

Registration Number: NCT00561418

Locations: 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States

Hatha Yoga in Improving Physical Activity, Inflammation, Fatigue, and Distress in Breast Cancer Survivors

Not Applicable

Completed

Conditions: Breast Cancer
Depression
Fatigue
Pain

Interventions: Procedure: Yoga Therapy

First Posted Date: 2007-06-14

Last Posted Date: 2014-05-05

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 200

Registration Number: NCT00486525

Locations: 🇺🇸
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Contrast of Buffered Vs. Unbuffered Lidocaine in Bone Marrow Biopsies

Not Applicable

Completed

Conditions: Pain

Interventions: Drug: lidocaine

First Posted Date: 2007-04-05

Last Posted Date: 2017-04-04

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 49

Registration Number: NCT00456872

Locations: 🇺🇸
The Ohio State University James Cancer Hospital, Columbus, Ohio, United States

Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma

Phase 1

Completed

Conditions: Renal Cancer
Melanoma

Interventions: Drug: Aldesleukin
Drug: Sorafenib

First Posted Date: 2007-01-04

Last Posted Date: 2017-02-20

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 17

Registration Number: NCT00418496

Locations: 🇺🇸
Ohio State University, Columbus, Ohio, United States

Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma

Phase 2

Completed

Conditions: Anaplastic Oligodendroglioma
Oligoastrocytoma, Mixed

First Posted Date: 2006-08-10

Last Posted Date: 2017-11-30

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 1

Registration Number: NCT00362570

Locations: 🇺🇸
Ohio State University, Columbus, Ohio, United States

Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases

Phase 1

Completed

Conditions: Brain Tumor
Brain Metastases

Interventions: Drug: carboplatin
Drug: temozolomide

First Posted Date: 2006-08-10

Last Posted Date: 2017-06-01

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 17

Registration Number: NCT00362817

Locations: 🇺🇸
Ohio State University, Columbus, Ohio, United States

CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas

Phase 1

Completed

Conditions: Non-Hodgkin's Lymphoma

Interventions: Drug: CHOP
Drug: Alemtuzumab
Procedure: Plasma Samples

First Posted Date: 2006-05-09

Last Posted Date: 2017-01-20

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 24

Registration Number: NCT00323323

Locations: 🇺🇸
Ohio State University, Columbus, Ohio, United States

Interferon Alpha-2b (Intron A) for Metastatic or Unresectable Clear Cell Renal Carcinoma

Phase 2

Withdrawn

Conditions: Renal Cancer

First Posted Date: 2006-02-17

Last Posted Date: 2013-05-23

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Registration Number: NCT00293527

Pemetrexed Chemotherapy in Poor-Risk Patients With Advanced Head and Neck Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: Pemetrexed

First Posted Date: 2006-02-17

Last Posted Date: 2020-02-10

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 5

Registration Number: NCT00293579

Locations: 🇺🇸
Ohio State University, Columbus, Ohio, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy